These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3815730)

  • 41. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
    J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
    Morrell LM; Bach A; Richman SP; Goodman P; Fleming TR; MacDonald JS
    Cancer; 1991 Jan; 67(2):363-6. PubMed ID: 1985731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
    Kemeny NE; Schneider A; Martin DS
    Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
    [No Abstract]   [Full Text] [Related]  

  • 44. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
    Chan TC; Howell SB
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):721-7. PubMed ID: 2714348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 46. Phase I study of continuous-infusion PALA and 5-FU.
    Ardalan B; Jamin D; Jayaram HN; Presant CA
    Cancer Treat Rep; 1984 Mar; 68(3):531-4. PubMed ID: 6231102
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
    Weiss GR; Ervin TJ; Meshad MW; Kufe DW
    Cancer Treat Rep; 1982 Feb; 66(2):299-303. PubMed ID: 7055815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
    Chiuten DF; Valdivieso M; Bedikian A; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
    Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pilot study of PALA and 5-FU in patients with advanced cancer.
    O'Connell MJ; Powis G; Rubin J; Moertel CG
    Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
    Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
    Rubin J; Schutt AJ; O'Connell MJ; Gertz MA; Moertel CG
    Am J Clin Oncol; 1984 Oct; 7(5):523-5. PubMed ID: 6507373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanism-based model for tumor drug resistance.
    Kuczek T; Chan TC
    Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
    Casper ES; Michaelson RA; Kemeny N; Martin DS; Young CW
    Cancer Treat Rep; 1984 Mar; 68(3):539-41. PubMed ID: 6704982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
    Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
    Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B
    Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
    Redei I; Green F; Hoffman JP; Weiner LM; Scher R; O'Dwyer PJ
    Invest New Drugs; 1994; 12(4):319-21. PubMed ID: 7775133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
    Wadler S; Gleissner B; Hilgenfeld RU; Thiel E; Haynes H; Kaleya R; Rozenblit A; Kreuser ED
    Eur J Cancer; 1996 Jun; 32A(7):1254-6. PubMed ID: 8758262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
    Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.